Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 6,416 | $34.28 | $219,940.48 |
DisclosureSEC source: 0001225208-17-005106 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,441 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantCommon Stock | 12,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005106 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,857 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 3,857 | $34.28 | $132,217.96 |
DisclosureSEC source: 0001225208-17-005108 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,192 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
OLSON LAURIE JExecutive Vice President
|
Tax withholdingCommon Stock | 2,667 | $34.28 | $91,424.76 |
DisclosureSEC source: 0001225208-17-005109 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,569 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
OLSON LAURIE JExecutive Vice President
|
Tax withholdingCommon Stock | 2,638 | $34.28 | $90,430.64 |
DisclosureSEC source: 0001225208-17-005109 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,236 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantCommon Stock | 7,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005109 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,874 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 55,609 | $34.28 | $1,906,276.52 |
DisclosureSEC source: 0001225208-17-005110 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,531 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 53,609 | $34.28 | $1,837,716.52 |
DisclosureSEC source: 0001225208-17-005110 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,140 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantCommon Stock | 110,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005110 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,749 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 9,702 | $34.28 | $332,584.56 |
DisclosureSEC source: 0001225208-17-005111 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,515 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantCommon Stock | 17,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005111 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,217 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 15,957 | $34.28 | $547,005.96 |
DisclosureSEC source: 0001225208-17-005112 · doc4.xml · nonDerivative · entry 3 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,494 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 15,779 | $34.28 | $540,904.12 |
DisclosureSEC source: 0001225208-17-005112 · doc4.xml · nonDerivative · entry 2 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,451 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC |
YOUNG JOHN DGroup President
|
GrantCommon Stock | 30,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005112 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,230 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 13:35 UTC |
BLAYLOCK RONALD EDirector
|
GrantPhantom Stock Units · Derivative | 5,504.991 | $34.06 | $187,499.99 |
DisclosureSEC source: 0001225208-17-004632 · doc4.xml · derivative · entry 1 BLAYLOCK RONALD E · CIK 0001214686 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,504.991 Underlying: Common Stock · 5,504.991 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:10 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 20,216 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004769 · doc4.xml · derivative · entry 8 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,216 Underlying: Common Stock · 20,216 shares Expires 2024-02-23 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:10 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 24,351 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004769 · doc4.xml · derivative · entry 7 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,351 Underlying: Common Stock · 24,351 shares Expires 2022-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:10 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionStock Appreciation Rights · Derivative | 36,408 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004769 · doc4.xml · derivative · entry 6 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,408 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:10 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 17,627 | $32.49 | $572,701.23 |
DisclosureSEC source: 0001225208-17-004769 · doc4.xml · nonDerivative · entry 4 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,450 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:10 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 6,996 | $34.06 | $238,283.76 |
DisclosureSEC source: 0001225208-17-004769 · doc4.xml · nonDerivative · entry 3 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,077 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:10 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 4,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004769 · doc4.xml · nonDerivative · entry 2 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,073 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:10 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionCommon Stock | 36,408 | $21.03 | $765,660.24 |
DisclosureSEC source: 0001225208-17-004769 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
BOURLA ALBERTGroup President
|
GrantStock Appreciation Rights · Derivative | 121,294 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004771 · doc4.xml · derivative · entry 7 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,294 Underlying: Common Stock · 121,294 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
BOURLA ALBERTGroup President
|
GrantStock Appreciation Rights · Derivative | 146,104 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004771 · doc4.xml · derivative · entry 6 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,104 Underlying: Common Stock · 146,104 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
BOURLA ALBERTGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 42,476 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004771 · doc4.xml · derivative · entry 5 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,476 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
BOURLA ALBERTGroup President
|
Tax withholdingCommon Stock | 20,565 | $32.49 | $668,156.85 |
DisclosureSEC source: 0001225208-17-004771 · doc4.xml · nonDerivative · entry 3 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,808 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
BOURLA ALBERTGroup President
|
Tax withholdingCommon Stock | 8,101 | $34.06 | $275,920.06 |
DisclosureSEC source: 0001225208-17-004771 · doc4.xml · nonDerivative · entry 2 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,373 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
BOURLA ALBERTGroup President
|
Exercise / conversionCommon Stock | 42,476 | $21.03 | $893,270.28 |
DisclosureSEC source: 0001225208-17-004771 · doc4.xml · nonDerivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 121,294 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004770 · doc4.xml · derivative · entry 7 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,294 Underlying: Common Stock · 121,294 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 146,104 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004770 · doc4.xml · derivative · entry 6 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,104 Underlying: Common Stock · 146,104 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 218,447 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004770 · doc4.xml · derivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 218,447 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 105,761 | $32.49 | $3,436,174.89 |
DisclosureSEC source: 0001225208-17-004770 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,154 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 53,850 | $34.06 | $1,834,131.00 |
DisclosureSEC source: 0001225208-17-004770 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,915 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionCommon Stock | 218,447 | $21.03 | $4,593,940.41 |
DisclosureSEC source: 0001225208-17-004770 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 592,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 121,294 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004772 · doc4.xml · derivative · entry 7 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,294 Underlying: Common Stock · 121,294 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 146,104 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004772 · doc4.xml · derivative · entry 6 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,104 Underlying: Common Stock · 146,104 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 218,447 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004772 · doc4.xml · derivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 218,447 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 105,761 | $32.49 | $3,436,174.89 |
DisclosureSEC source: 0001225208-17-004772 · doc4.xml · nonDerivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,315 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 53,839 | $34.06 | $1,833,756.34 |
DisclosureSEC source: 0001225208-17-004772 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,076 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:21 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 218,447 | $21.03 | $4,593,940.41 |
DisclosureSEC source: 0001225208-17-004772 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:24 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 84,232 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004773 · doc4.xml · derivative · entry 4 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,232 Underlying: Common Stock · 84,232 shares Expires 2024-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:24 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 101,461 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004773 · doc4.xml · derivative · entry 3 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,461 Underlying: Common Stock · 101,461 shares Expires 2022-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:24 UTC |
HILL CHARLES HExecutive Vice President
|
Tax withholdingCommon Stock | 22,837 | $34.06 | $777,828.22 |
DisclosureSEC source: 0001225208-17-004773 · doc4.xml · nonDerivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,553 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 27,965 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004774 · doc4.xml · derivative · entry 7 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,965 Underlying: Common Stock · 27,965 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 33,685 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004774 · doc4.xml · derivative · entry 6 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,685 Underlying: Common Stock · 33,685 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 21,238 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004774 · doc4.xml · derivative · entry 5 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,238 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 10,282 | $32.49 | $334,062.18 |
DisclosureSEC source: 0001225208-17-004774 · doc4.xml · nonDerivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,778 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 4,112 | $34.06 | $140,054.72 |
DisclosureSEC source: 0001225208-17-004774 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,060 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionCommon Stock | 21,238 | $21.03 | $446,635.14 |
DisclosureSEC source: 0001225208-17-004774 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:30 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 60,647 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004775 · doc4.xml · derivative · entry 7 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,647 Underlying: Common Stock · 60,647 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.